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Abstract
Pruritus is associated with various skin diseases, dry skin, and with it an impaired skin barrier func-
tion. The study objective was to investigate short-term and long-term effects of two emollients on
symptoms and skin barrier functions in xerotic eczema. Randomized, double-blind, study enrolling
females/males, with bilateral itching. Two emollients, containing lactic acid and refined almond oil
with/without polidocanol were administered on left versus right body sides. Itching severity, skin
moisture, lipid content, and pH were assessed on Day 1, within 30–120 min after first administra-
tion, and on Days 7 and 14, and compared with baseline assessments. Severity of itching decreased
30 min after first administration of both emollients compared with baseline (p < .0001) and
reached a maximum reduction of 63% (p < .0001) and 69% (p < .0001) on Day 14. Skin moisture
and lipid content increased after first application, and further ameliorated within 14 days of treat-
ment (p < .0001). Both emollients were tolerated well, and only a few adverse events were
reported. This study confirmed the clinical efficacy of the two study emollients to substantially
reduce itching already after first administration, and restore skin barrier integrity and thus should
be considered as therapeutic approach for xerotic eczema.
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1 | INTRODUCTION
Pronounced pruritus is one of the most prominent symptoms of many
skin diseases such as atopic or xerotic eczema and psoriasis (AWMF-
S2k, 2015; AWMF-S2k, 2016; Darsow, Pfab, Valet, Tölle, & Ring, 2012;
Puschmann, Melzer, & Welzel, 2003). The clinical picture and symp-
toms, notably the often unbearable chronic pruritus as a major symptom
of dry skin diseases, may induce severe psychological stress with a neg-
ative impact on wellbeing and daily activities (AWMF-S2k, 2015;
AWMF-S2k, 2016; Puschmann et al., 2003). Medical guidelines expect
a dual action from effective therapies; a quick relief of the itching during
the acute phase and sustained relief during the chronic phase (AWMF-
S2k, 2015; AWMF-S2k, 2016). Topical glucocorticoids reduce inflam-
mation and itching in the acute treatment phase. However, administra-
tion of topical glucocorticoids for longer treatment periods is not
recommended and limited due to the high potential of adverse events
(Carr, 2013). Beside the pruritus treatment, a sustained restoration of
the skin barrier by normalization of moisture and lipid contents is para-
mount for effective treatment (Weisshaar, 2009; Nebus, 2012).
Over recent years it became clear, that a genetic disposition
toward an impaired skin barrier function is a major cause for the
manifestation of dry skin diseases like atopic dermatitis. Certain
genetic mutations may lead to altered compositions of essential
bilayer components, which impair skin barrier integrity (Jungersted
et al., 2010; McLean, 2016; Rabionet, Gorgas, & Sandhoff, 2014;
Vyumvuhore, Tfayli, Manfaie, & Baillet-Guffroy, 2013). Filaggrin is
essential for the regulation of epidermal homeostasis. Profilaggrin
undergoes processing in the upper stratum corneum, a process dur-
ing which free amino acids are released that assist in water retention
and function as natural moisturizing factors (NMF) (Ovaere, Lippens,
Received: 26 October 2017 Revised: 30 November 2017 Accepted: 17 July 2018
DOI: 10.1111/dth.12692
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2018 The Authors. Dermatologic Therapy published by Wiley Periodicals, Inc.
Dermatologic Therapy. 2018;31:e12692. wileyonlinelibrary.com/journal/dth 1 of 7
https://doi.org/10.1111/dth.12692
Vandenabeele, & Declercq, 2009; Paloncyova, 2015). Ceramides are
sphingolipids which are of major importance for the homeostasis of
the stratum corneum. Among the various ceramides, it is predomi-
nantly the linoleic acid containing ceramide I, which is crucial for the
stratum corneum integrity (Liu, Xia, Chen, Xue, & Zheng, 2015).
In addition, salts of lactic acid have been shown to exhibit mois-
turizing and barrier stabilizing effects (Sugawara, Kikuchi, Tagami,
Aiba, & Sakai, 2012; Vyumvuhore et al., 2013). Lactic acid is a physio-
logically relevant NMF in human sweat as well as significantly rehy-
drates the skin when added topically (Sugawara et al., 2012). Topical
treatments with a combination of moisturizing factors, such as lactic
acid, plus lipophilic components, such as natural fatty oils or linoleic
acid, showed clinical evidence in stabilizing the skin barrier by restoring
moisture and modifying the sphingolipid bilayer in the stratum corneum
(Hon, Leung, & Barankin, 2013; Jungersted et al., 2010; McLean, 2016;
Rabionet et al., 2014; Van Smeden et al., 2014). Polidocanol has been
used as a compound for oral mucosa preparations, in emollients to treat
itching for more than 50 years, and recently in parenteral formulations for
sclerotherapy (Angerer et al., 2006; Ballmer-Weber & Dummer, 2007;
Berberian, Gorman, Drobeck, Coulston, & Slighter, 1965; Goldman, 1989;
Matthies, 1993; Puschmann et al., 2003; Ring & Fröhlich, 1985; Siems &
Soehring, 1952; Soehring, Frahm, & Mletzko, 1952; Ständer et al., 2006).
Despite the long usage of this compound, we could only find one double-
blind, placebo-controlled clinical study investigating the effects of polido-
canol versus placebo on itching in healthy volunteers. The cowhage
induced itching test-method showed that polidocanol reduced itching
during the 30 min test period (Hawro et al., 2014). Other case and open-
label studies with formulations containing polidocanol showed beneficial
effects on itching, which, however, could not be attributed solely to poli-
docanol (Hauss, Proppe, & Matthies, 1993; Puschmann, 1992; Schöpf,
1992; Vieluf, Matthies, & Ring, 1992).
The two emollients investigated in this study have been devel-
oped for xerotic skin conditions, including atopic dermatitis. Both
emollients (AL and AC) are oil/in water formulations containing lactic
acid, almond oil, and a slightly different lipid content. This results in a
distinctive consistency reflecting specific preferences of patients. In
addition, AC contains in addition polidocanol.
The primary aim of our study was to investigate the short-term
and long-term effects on itching and restoration of skin barrier func-
tions in patients with xerotic eczema including atopic dermatitis com-
pared with pre-treatment condition (change to baseline) for each of
the two emollients.
2 | PATIENTS/METHODS
2.1 | Study design
This randomized, double-blind, two-arm intra-individual (right–left
body sides), multicenter study was conducted in four dermatological
departments of Swiss hospitals. The Swiss Health Authority and
independent Ethics Committees approved the study according to
Swiss regulations. The inclusion criteria were: females and males,
18–75 years old, with sensitive or mildly inflamed (fissured, scaly)
skin conditions due to xerotic eczema including atopic dermatitis,
moderate to severe itching of comparable right–left severity on arms
or legs, and treatments (emollients or creams) containing active sub-
stances, including but not limited to lactic acid, urea or polidocanol
were not allowed for at least 3 days before the baseline visit (admin-
istration of cosmetic products was permitted). The use of cortisone
or calcineurin inhibitors containing lotions, immunosuppressive
drugs, retinoids, and UV-light therapy within 4 weeks prior to inclu-
sion and during the study was prohibited.
2.2 | Study population
Patients were enrolled after signing the written informed consent. Two
medicinal emollients registered in Switzerland containing lactic acid (5%)
and refined almond oil (10%) rich in linoleic acid (20 to 30%) (Antidry
Lotion [AL]) or lactic acid (5%), refined almond oil (10%) and in addition
the antipruritic compound polidocanol (5%) (Antidry Calm [AC]) were
provided in 500 mL flasks with dispenser blinded and randomized to be
administered on the right versus left body side (labeling indicated admin-
istration side with “R” or “L”) twice daily. At Baseline (BL), prior to first
administration of the study emollients, the extremities with the most
severe bilateral itching (arms or legs) were defined as study areas. The
patients were instructed to apply the study emollients twice daily (morn-
ing and evenings). The study emollient to be used on the left arm and
leg was dispensed into the right hand, and vice versa. For correct dos-
age, the dispenser had to be pressed two times (2.4 mL) for treatment
of the arms, or three times (3.6 mL) for treatment of the legs. To confirm
adherence to therapy, the weight of study flasks was determined before
and after the first administration, on Days 7 and 14, respectively. Patient
reported outcomes are the state-of-the-art evaluation tool to assess
both, short-term and long-term effects on itching (Liu et al., 2015;
Pereira & Stander, 2017; Puschmann et al., 2003). As published in
Puschmann et al. (2003) and recommended in medical guidelines
(AWMF-S2k, 2016), the severity of itching was assessed by a
visual analogue scale (VAS) 0–100 (100 mm scale). The current
itching score was recorded on Day 1, before the first administra-
tion under instruction by the study nurse and after 30, 60, 90, and
120 min, respectively. The 24 h itching score (maximal itching
severity within the last 24 hours) was recorded at BL (before first
administration), and on Days 7 and 14. Since restoration of epider-
mal barrier properties is one of the most important features to
improve symptoms of dry skin diseases, measurements of skin
moisture, lipid content and pH were performed at short-term and
long-term intervals (Courage + Khazaka electronic GmbH, 2012;
Hussain et al., 2016). Skin moisture, lipid content and pH were
measured using a DERMA Unit SSC 3 device (Courage + Khazaka
electronic GmbH, 2012). Clinical efficacy and tolerability evalu-
ated by investigators and patients were assessed using a 4-point
Likert Scale (0 = unsatisfactory, 1 = moderate, 2 = good, 3 = very
good) (Jamieson, 2004).
2.3 | Statistical analysis
Based on study result of Puschmann et al. (2003), a sample size of
42 had 80% power to detect a difference in VAS means of 0.83 (Delta
of BL versus VAS actual score[s] within 2 hr after administration of AL
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and AC compared with pre-treatment BL), assuming a standard devia-
tion of differences of 1.67 using a paired t-test with a 0.0125 one-
sided significance study area and time point (30, 60, 90, and 120 min).
Data are shown as mean (SD). In order to compare BL and follow up
data, Wilcoxon signed rank test or t-test were performed depending
whether the data were normally distributed or not to calculate p-
values. To compensate for estimated dropouts, 48 patients needed to
be included. The current itching score was calculated as change to BL
for each patient, each study area (treated with AL and AC), and each
time point (30, 60, 90, and 120 min).
3 | RESULTS
Fifty patients were included at four centers between February 2015
and May 2016. At all, five patients (one screening failure, four proto-
col deviations (three related to low severity of itching on Day 1 and
one non-compliance) were excluded from the efficacy analysis popu-
lation (EAP). Forty-five patients were included in the EAP and one
premature termination was reported due to bilateral exacerbation of
pruritus. The majority of patients were females (67%) and the mean
age was 52 (18) years. The mean BL values of itching severity and
skin parameters for the study areas treated with AL and AC were
comparable (Figure 1 and Table 1). The 24 hr itching scores were
slightly higher compared with the current itching scores (Figure 1a
and b).
After the first administration of AL on Day 1, the mean current
itching score decreased from 54.6 (15.4) at BL to 32.9 (22.9)
already after 30 min (p < .0001), and then further decreased after
60 and 90 min, toward 24.6 (19.9) after 120 min (p < .0001)
(Figure 1). After the first administration of AC, the mean (SD) current
itching score decreased from 54.3 (15.4) at BL to 32.3 (22.2) after
30 min (p < .0001), continued to decrease after 60 and 90 min and
dropped to 22.8 (21.2) after 120 min (p < .0001) (Figure 1). Two
hours after first administration of AL and AC, the current itching score
was reduced by 55% (p < .0001) and 58% (p < .0001), respectively.
On study areas treated with AL, the mean 24 h itching score
decreased from 64.6 (14.5) at BL to 23.4 (27.4) on Day
14 (p < .0001), and on those treated with AC from 63.9 (15.8) at BL
to 19.5 (25.1) on Day 14 (p < .0001) (Figure 1). The mean 24 h itch-
ing scores were reduced after 14 days of twice daily administration of
AL and AC by 63% (p < .0001) and 69% (p < .0001), respectively. To
compare the short term effect on severity of itching between the two
study emollients AL and AC, the differences from BL (Δ30, Δ60, Δ90,
FIGURE 1 (a) Mean (SD) current itching score on study areas treated with AL and AC on Day 1, before (BL), and 30, 60, 90, and 120 min after
first administration of the two study emollients, and (b) mean (SD) 24 hr itching score on study areas treated with AL and AC on Day 1 (BL), on
Day 7 and Day 14
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and Δ120 min, calculated as area under the curve [AUC],
e.g.,AUC0–30, AUC30–60, AUC60–90, and AUC90–120) were summarized
as AUC0–120 per patient and study area. An exploratory paired t-test
was performed on the EAP and revealed that the effects of AL and
AC on reducing the severity of itching were very similar (p = .9384).
Treatment with AL increased the skin moisture by 40%
(p < .0001) from 27.8 (8.7) at BL to 39.0 (12.2) (p < .0001) on Day
14, and the skin lipid content increased from 0.5 (1.1) at BL to 22.9
(33.5) on Day 14 (p < .0001) (Table 1). Treatment with AC increased
the skin moisture by 41% (p < .0001), from 28.1 (9.4) at BL to 38.9
(14.7) (p < .0001) on Day 14, and the skin lipid content from 0.6
(1.0) at BL to 22.6 (33.6) on Day 14 (p < .0001) (Table 1). The skin
pH of the two study areas at BL was 5.9 (0.8) and 6.0 (0.7), respec-
tively, and did not change during the 14-day treatment period with AL
and AC.
Clinical efficacy evaluated by investigators (CEI) and by patients
(CEP) were comparable and similar for both, AL and AC. The propor-
tions of “good/very good” ratings ranged from 76% to 80% for CEI,
and from 69% to 84% for CEP. The proportion of “very good” CEP
ratings increased within 120 min after first administration of AL and
AC, and further till Day 14 (Figure 2). Similarly, clinical tolerability
evaluated by investigators (CTI) and by patient (CTP) were comparable
for AL and AC, with proportions of “good/very good” ratings of 73 to
90% for CTI, and of 82 to 92% for CTP. The highest proportions of
“very good” CTI were recorded on Day 14 (49 and 47%, respectively)
and “very good” CTP on Day 7 (53 and 55%, respectively).
Recording the weight of AL and AC flasks revealed a mean weight
of 551.9 (4.5) and 559.2 (2.5) grams, respectively, before first
administration, and a consumption of 6.6 (4.2) and 7.2 (4.2) g,
respectively, after first administration at the centers, and 72.2 (21.7)
and 73.7 (29.1) g, respectively, on Day 7, and 158.5 (98.9) and
142.2 (53.3) g, respectively, on Day 14.
Six patients (12.2%) exposed to AL and AC treatment experienced
seven unilateral or bilateral treatment emerged adverse reactions
(TEAR). No serious TEAR was reported, and 6 out of the 7 TEARs
were mild or moderate. Treatment with AL and AC resulted in six and
five TEARs, respectively. The following TEAR were reported: Itching
[shortly after first administration (n = 2, bilateral with AL and AC)],
TABLE 1 Skin moisture (CU values), skin lipid content (PU values) and skin pH on study areas treated with AL and AC on screening visit, BL, Day
1 (120 min), Day 7 and Day 14 (mean  SD and mean  SD change from BL)
Skin moisture
AL Change from BL AC Change from BL
Mean SD Mean SD p-value* N = Mean SD Mean SD p-value*
Screening 28.7 10.4 44 28.8 11.1
BL 27.8 8.7 45 28.1 9.4
D1–120 min 36.1 12.6 8.3 8.1 <.0001 45 36.2 13.5 8.1 8.3 <.0001
Day 7 39.0 14.7 11.4 10.4 <.0001 44 39.7 13.6 11.8 10.3 <.0001
Day 14 39.0 12.2 11.5 10.0 <.0001 43 38.9 14.7 11.1 12.0 <.0001
Skin lipid content
AL Change from BL AC Change from BL
Mean SD Mean SD p-value* N = Mean SD Mean SD p-value*
Screening 0.7 1.4 44 1.0 2.4
BL 0.5 1.1 45 0.6 1.0
D1–120 min 54.0 58.1 53.4 57.9 <.0001 45 60.0 61.9 59.4 61.5 <.0001
Day 7 14.2 19.5 13.7 19.5 <.0001 44 17.5 30.1 16.9 30.1 <.0001
Day 14 22.9 33.5 22.3 33.1 <.0001 43 22.6 33.6 22.0 33.2 <.0001
Skin pH
AL Change from BL AC Change from BL
Mean SD Mean SD p-value* N = Mean SD Mean SD p-value*
Screening 5.9 0.7 44 5.9 0.7
BL 5.9 0.8 45 6.0 0.7
D1–120 min 5.8 0.4 −0.1 0.5 .2511 45 5.8 0.4 −0.2 0.5 .0058
Day 7 5.9 0.6 0.0 0.7 .7487 44 5.8 0.5 −0.1 0.6 .0844
Day 14 6.0 0.5 0.1 0.8 .3606 43 6.0 0.5 0.0 0.7 .8976
The skin was not washed before any skin measurements. Skin moisture was measured by means of corneometry and expressed in arbitrary corneo-
metric units (CU). CU values <30 (on forearm) reflect very dry skin, CU values of 30–45 dry to normal skin and CU values >45 high skin moisture.
Skin lipid content was measured using sebumetry (before first administration on Day 1, and 4–6 hr after previous administration of study emol-
lients) and expressed in photometric units (PU). PU values of 0–6 (on arms or legs) reflect absence to very low skin lipid content, and PU values >6
represent normal skin lipid content. The pH was measured with a flat-topped glass electrode connected to the voltmeter of the device. Calibrations
of the corneometer, sebumeter, and pH-meter were performed according to the instructions of the manufacturer. Measurements were performed
on a defined soft skin area within the study area without hair in the following sequence: Skin moisture, skin lipid, and skin pH, and at standard room
conditions (20 C and 40–60% air humidity). Each skin parameter was measured three times, all values were recorded, and means of triplicates
were calculated. Efficacy analysis population (EAP)/*t-test for parameters ‘Skin Moisture’ and ‘Skin pH’, Wilcoxon signed rank test for parameter ‘Skin
Lipid Content’.
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itching eczema (n = 1, unilateral with AL), worsening of eczema (n = 1,
bilateral with AL and AC leading to premature termination on Day 7),
exacerbation of pruritus (n = 2, one bilateral with AL and AC and one
unilateral with AC), and contact dermatitis (n = 1, unilateral with AL).
4 | DISCUSSION
A broad range of topical emollients containing various active sub-
stances are used to treat xerotic eczema including atopic dermatitis
(Nebus, 2012). Literature search revealed only a few publications
investigating the effects of ammonium lactate (Rogers, Callen,
Wehr, & Krochmal 1989), hyaluronic acid-based foam (Draelos,
2011), creams containing ceramides and magnesium (Draelos,
2011; Koppes et al., 2016), levomenol and/or heparin (Arenberger,
Arenbergerová, Drozenová, Hladíková, & Holcová, 2011), glycerol
(Breternitz, Kowatzki, Langenauer, & Elsner, 2008), or a
petrolatum-based emollient (Kucharekova, Van De Kerkhof, & Van
Der Valk, 2003), while many RCTs with other active substances
such as corticosteroids, calcineurin inhibitors, and cyclosporine have
been published (Shim et al., 2016; Hussain et al., 2016; Jensen et al.,
2013; Silverberg, 2014; Ortonne et al., 2003).
Our investigation represents one of the first randomized, double-
blind studies in patients assessing both, a sequential short-term
(30, 60, 90, and 120 min after first administration) and a long-term
(over 7 and 14 days) effectiveness of two emollients (each compared
with baseline) administered in a two-arm, intra-individual (right versus
left body side) approach. This represents a common practice in order
to minimize individual variations of skin sensation (Jensen et al., 2013;
Ortonne et al., 2003).
Here, we could demonstrate that the application of the two study
emollients lead to a rapid and significant reduction of pruritus in
patients with xerotic eczema and associated moderate to severe pruri-
tus. An effect on the current itching score could already be observed
within 2 hr after the first application of the emollients. The twice-daily
application of the study emollients over 2 weeks resulted in a marked
decrease of the 24 hr itching score.
The short- and long-term effects of both study emollients, AL and
AC, on itching were similar. This raised the question on the effect of
polidocanol in AC. It should be emphasized, that our study was not
intended, and therefore not designed to show differences on itching
between AL and AC, and by that an effect of polidocanol. As to our
knowledge, randomized, double-blind, controlled (placebo or compara-
tor) clinical trials with polidocanol in patients have not been
FIGURE 2 Clinical efficacy of AL and AC evaluated by investigators and patients on Day 1 (120 min), Day 7, and Day 14 using a 4-point Likert
scale showing proportion of “very good,” “good,” “moderate,” and “satisfactory” ratings. Efficacy Analysis Population (EAP): n = 45 on Day 1 (120
min), n = 44 on Day 7, and n = 43 on Day 14. Denominator for percentages was number EAP on Day 1 (N = 45)
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conducted (AWMF-S2k, 2015). A recent study using an itch-
provoking test-method in healthy volunteers showed a clear antipruri-
tic effect of polidocanol when PAR-2 dependent itch pathways (asso-
ciated with atopic dermatitis) were provoked (Hawro et al., 2014).
Itching was significantly reduced within 10–24 min after administra-
tion of an aqueous polidocanol solution versus placebo (water)
(Hawro et al., 2014). The effect of polidocanol seems to be rapid and
transient, and therefore the effect of polidocanol could not be shown
in patients with pruritus when assessed at 30 min or later. Accord-
ingly, effects specifically attributed to polidocanol need to be further
investigated in an appropriate clinical setting.
Skin moisture and lipid content of the Stratum corneum are
thought to be essential for the maintenance of the skin barrier
(Jensen et al., 2013). Here we show that the reduction of pruritus
parallels an increase of skin moisture and lipid content. Two weeks
application of AL and AC, resulted in a significant increase of skin
moisture and lipid content reflecting normalization of the skin bar-
rier function. Sebumetry measurements were conducted with a
minimum interval of 4–6 hr after last administration of AL and AC,
except at Day 1. This explains why the lipid content 2 hr after first
administration was higher compared with the levels after multiple
administrations on Days 7 and 14. Interestingly, the application of
AL and AC had only a very slight effect on the pH of the skin. This
observation might be due to the fact that the pH at baseline was
only minimally increased. A 2-week application of the study emol-
lients was not sufficient to completely normalize the pH. Carry-
over effects from the AL-treated to the AC-treated body side seem
unlikely, since patients were instructed to use the left hand for the
right side treatment and vice versa.
Adherence to dose regimens is essential for the effectiveness of
treatments. Controlling the flask weight throughout the study con-
firmed that all patients of the EAP adhered to the treatment regimen.
Also, the tolerability of the study medication is an important criterion
for patients’ compliance. The clinical efficacy rated by patients and
investigators was positive and congruent, and more than 70% of the
patients and investigators rated the effect and tolerability of AL and
AC as very good or good.
Although AL and AC are tolerated very well in general, treatment
related adverse effects should be monitored. One patient had to stop
the application of the study emollients due a contact dermatitis.
Whether the dermatitis was related to skin irritation or a contact
allergy has not been assessed.
5 | CONCLUSION
This clinical trial demonstrated that emollients containing refined
almond oil rich in linoleic acid and lactic acid as moisturizing factor
may reduce pruritus in patients with xerotic eczema. This effect could
be observed as early as 30 min after first application and was even
more pronounced after twice daily application of the emollients for
2 weeks. Furthermore, the results of this study clearly demonstrated
that restoration of the skin barrier function and reduction itching are
tightly related to each other. Because of the excellent efficacy and
tolerability profile, emollients such as AL and AC should be considered
as treatment for xerotic eczema.
ACKNOWLEDGMENTS
Statistical considerations and sample size calculation was performed
by Godehard Hoexter, and the statistical analysis was conducted by
Marina Tetyusheva, Köhler eClinical Ltd., Freiburg, Germany, funded
by Merz Pharma (Schweiz).
CONFLICT OF INTEREST
This study had been initiated and sponsored by Merz Pharma
(Schweiz) AG. Eckhart Wildi is head of Medical & Regulatory Affairs,
Merz Pharma (Schweiz) AG Hegenheimermattweg 57, CH-4123
Allschwil.
ClinResearch Ltd. has been contracted by Merz Pharma (Schweiz)
to plan and conduct the study. Urs E. Gasser was the Medical Writer
for the protocol, related study documents and clinical study report.
Dagmar Simon, was assigned as principal coordinating investigator
for this study, Stephan Nobbe, Siegfried Borelli and Omar Hasan-Ali
were principle investigators at the other participating sites, and Mirjam
Nägeli, Pascale Kränzlin, Michael Kunz were co-investigators.
All authors have no conflict of interest relevant to the content of
the submission.
ORCID
Urs Erwin Gasser https://orcid.org/0000-0002-1546-3433
REFERENCES
Angerer, J., Bernauer, U., Chambers, C., Chaudhry, Q., Degen, G., Nielsen,
E., … White IR. (2006). Scientific Committee on Consumer Safety:
SCCS/1457/11(Addendum to the SCCP/1130/07).
Arenberger, P., Arenbergerová, M., Drozenová, H., Hladíková, M., &
Holcová, S. (2011). Effect of topical heparin and levomenol on atopic
dermatitis: A randomized four-arm, placebo-controlled, double-blind
clinical study. Journal of the European Academy of Dermatology and
Venereology, 25(6), 688–694.
AWMF-S2k (2015). Leitlinie Dermatologie: Neurodermitis.
AWMF-S2k (2016). Leitlinie Dermatologie: Chronischer Pruritus.
Ballmer-Weber, B. K., & Dummer, R. (2007). Pruritus in frequent skin dis-
eases and therapeutic options. Praxis, 96(4), 107–111.
Berberian, D. A., Gorman, W. G., Drobeck, H. P., Coulston, F., &
Slighter, R. P. (1965). The toxicology and biological properties of
laureth 9 - a polyoxyethylene laurylether, a new spermicidal agent.
Toxicology and Applied Pharmacology, 7, 206–214.
Breternitz, M., Kowatzki, D., Langenauer, M., & Elsner, P. (2008).
Placebo-controlled, double-blind, randomized, prospective study
of a glycerol-based emollient on eczematous skin in atopic dermati-
tis: Biophysical and clinical evaluation. Skin Pharmacology and Physiol-
ogy, 21(1), 39–45.
Carr, W.W. (2013). Topical calcineurin inhibitors for atopic dermatitis:
review and treatment recommendations. Paediatr Drugs, 15(4), 303-310.
Courage + Khazaka electronic GmbH. (2012). Information und Geb-
rauchsanweisung zum Kombigerät Derma Unit SSC 3:
Sebumeter®/Corneometer®/Skin-pH-Meter®, Mathias-Brüggen-Str.
91, 50,829 Köln/Germany. info@courage-khazaka.de.
Darsow, U., Pfab, F., Valet, M., Tölle, T. R., & Ring, J. (2012). Itch and
eczema. Chemical Immunology and Allergy, 96, 81–88.
Draelos, Z. D. (2011). A clinical evaluation of the comparable efficacy of
hyaluronic acid-based foam and ceramide-containing emulsion cream
6 of 7 SIMON ET AL.
in the treatment of mild-to-moderate atopic dermatitis. Journal of Cos-
metic Dermatology, 10, 185–188.
Goldman, P. M. (1989). Polidocanol (Aethoxysklerol) for Sclerotherapy of
superficial Venules and Teleangiectasias. Journal of Dermatologic Sur-
gery and Oncology, 15, 204–209.
Hauss, H., Proppe, A., & Matthies, C. (1993). Vergleichende Untersuchungen
zur Behandlung von trockener, juckender Haut mit einer Zubereitung
aus Harnstoff und Polidocanol sowie mit einer Linolsäure-haltigen Fett-
creme. Dermatosen, 41, 184–188.
Hawro, T., Fluhrl, J. W., Mengeaud, V., Redoules, D., Church, M. K.,
Maurer, M., & Metz, M. (2014). Polidocanol inhibits cowhage - but not
histamine-induced itch in humans. John Wiley & Sons NS. Published
by John Wiley & Sons Ltd. Experimental Dermatology, 2, 922–941.
Hon, K. L., Leung, A. K., & Barankin, B. (2013). Barrier repair therapy in
atopic dermatitis: An overview. American Journal of Clinical Dermatol-
ogy, 14(5), 389–399.
Hussain, Z., Sahudin, S., Thu, H. E., Shuid, A. N., Bukhari, S. N., &
Kumolosasi, E. (2016). Recent advances in pharmacotherapeutic para-
digm of mild to recalcitrant atopic dermatitis. Critical Reviews in Thera-
peutic Drug Carrier Systems, 33(3), 213–263.
Jamieson, S. (2004). Likert scales: How to (ab)use them. Medical Education,
38, 1212–1218.
Jensen, J. M., Weppner, M., Dähnhardt-Pfeiffer, S., Neumann, C.,
Bräutigam, M., Schwarz, T., … Proksch, E. (2013). Effects of pimecroli-
mus compared with triamcinolone acetonide cream on skin barrier
structure in atopic dermatitis: A randomized, double-blind, right–left
arm trial. Acta Dermato-Venereologica, 93(5), 515–519.
Jungersted, J. M., Scheer, H., Mempel, M., Baurecht, H., Cifuentes, L.,
Høgh, J. K., … Weidinger, S. (2010). Stratum corneum lipids, skin barrier
function and filaggrin mutations in patients with atopic eczema. Allergy,
65(7), 911–918.
Koppes, A., Charles, F., Lammers, L. A., Frings-Dresen, M., Kezic, S., &
Ruste-Meyer, T. (2016). Efficacy of a cream containing Ceramides and
magnesium in the treatment of mild to moderate atopic dermatitis: A
randomized, double-blind, emollient- and hydrocortisone-controlled
trial. Acta Dermato-Venereologica, 96, 948–953.
Kucharekova, M., Van De Kerkhof, P. C., & Van Der Valk, P. G. (2003). A
randomized comparison of an emollient containing skin-related lipids
with a petrolatum-based emollient as adjunct in the treatment of
chronic hand dermatitis. Contact Dermatitis, 48, 293–299.
Liu, M. L., Xia, L., Chen, X. Y., Xue, F., & Zheng, J. (2015). Topical applica-
tion of a linoleic acid-ceramide containing moisturizer exhibit thera-
peutic and preventive benefits for psoriasis vulgaris: A randomized
controlled trial. Dermatologic Therapy, 28, 373–382.
Matthies, C. (1993). Polidocanol - ein sicherer wirkstoff in der dermatolo-
gie. Dt Dermatol, 5, 542.
McLean, W. H. (2016). Filaggrin failure - from ichthyosis vulgaris to atopic
eczema and beyond. British Journal of Dermatology, 175(Suppl. 2), 4–7.
Nebus, C. M. (2012). Management of patients with atopic dermatitis: The
role of emollient therapy. Dermatology Research and Practice, 2012, 1–15.
Ortonne, J. P., Humbert, P., Nicolas, J. F., Tsankov, N., Tonev, S. D.,
Janin, A., … Dubertret, L. (2003). Intra-individual comparison of the
cutaneous safety and efficacy of calcitriol 3 microg g(−1) ointment and
calcipotriol 50 microg g(−1) ointment on chronic plaque psoriasis local-
ized in facial, hairline, retroauricular or flexural areas. British Journal of
Dermatology, 148(2), 326–333.
Ovaere, P., Lippens, S., Vandenabeele, P., & Declercq, W. (2009). The
emerging roles of serine protease cascades in the epidermis. Trends in
Biochemical Sciences, 34(9), 453–463.
Paloncyova, P. (2015). Structural changes in ceramide bilayers rationalize
increased permeation through stratum corneum models with shorter
acyl tails. The Journal of Physical Chemistry, 119, 9811–9819.
Pereira, M. P., & Stander, S. (2017). Assessment of severity and burden of
pruritus. Allergology International, 66(1), 3–7.
Puschmann, M. (1992). Experimentelle Untersuchungsergebnisse zur
Juckreiz-linderung, zur Hautfettung und zur Hautverträglichkeit einer
Harnstoff- und Polidocanol-haltigen Zubereitung. Aktuelle Dermatology,
18, 224–228.
Puschmann, M., Melzer, A., & Welzel, J. (2003). Großflächige Behandlung
juckender, sebostatischer Dermatosen mit einer Polidocanol-Urea-
Kombination. Aktuelle Dermatology, 29(3), 77–81.
Rabionet, M., Gorgas, K., & Sandhoff, R. (2014). Ceramide synthesis in the
epidermis. Biochimica et Biophysica Acta, 1841(3), 422–434.
Ring, J., & Fröhlich, H. H. (1985). Allgemeine juckreizstillende Massnahmen.
Wirkstoffe in der Dermatologischen Therapie (2nd ed., p. 181). Berlin:
Springer Verlag.
Rogers, R. S., Callen, J., Wehr, R., & Krochmal, L. (1989). Comparative effi-
cacy of 12% ammonium lactate lotion and 5% lactic acid lotion in the
treatment of moderate to severe xerosis. The Journal of the American
Academy of Dermatology, 21, 714–716.
Schöpf, E. (1992). Erscheinungsbilder trockener, juckender Dermatosen
und die Behandlung mit einer neuen, harnstoff- und polidocanolhalti-
gen Creme. Haut, 6, 1–7.
Shim, J. H., Park, J. H., Lee, J. H., Lee, D. Y., & Yang, J. M. (2016). Moistur-
izers are effective in the treatment of xerosis irrespectively from their
particular formulation: Results from a prospective, randomized,
double-blind controlled trial. JEADV, 30, 276–281.
Siems, K. J., & Soehring, K. (1952). Die Ausschaltung sensibler Nerven
durch peridurale und paravertebrale Injektion von Alkylpolyäthylenox-
ydäthern bei Meerschweinchen. Arzneim-Forsch, 2, 109–111.
Silverberg, J. I. (2014). Atopic dermatitis: An evidence-based treatment
update. American Journal of Clinical Dermatology, 15(3), 149–164.
Soehring, K., Frahm, M., & Mletzko, K. (1952). Beiträge zur Pharmakologie
der Alkyl-Polyäthylenoxydderivate. IV: Lokalanalgetische Wirkungen
und Bemerkungen zur vergleichenden Auswertung leitungshemmender
Substanzen. Archives Internationales De Pharmacodynamie Et De Théra-
pie, 91, 112–129.
Ständer, S., Weisshaar, E., Mettang, T., Szepietowski, J. C., Carstens, E.,
Ikoma, A., … Bernhard, J. (2006). Topische Cannabinoidagonisten: Eine
effektive, neue Möglichkeit zur Behandlung von chronischem Pruritus.
Hautarzt, 57, 390.
Sugawara, T., Kikuchi, K., Tagami, H., Aiba, S., & Sakai, S. (2012). Decreased
lactate and potassium levels in natural moisturizing factor from the
stratum corneum of mild atopic dermatitis patients are involved with
the reduced hydration state. Journal of Dermatologic Science, 66,
154–159.
Van Smeden, J., Janssens, M., Kaye, E. C., Caspers, P. J., Lavrijsen, A. P.,
Vreeken, R. J., … Bouwstra, J. A. (2014). The importance of free fatty
acid chain length for the skin barrier function in atopic eczema
patients. Experimental Dermatology, 23, 45–52.
Vieluf, D., Matthies, C., & Ring, J. (1992). Trockene, juckende Haut - ihre
Behandlung mit einer neuen Polidocanol-Harnstoff-Zubereitung. Zeits-
chrift für Hautkrankheiten, 67, 816–821.
Vyumvuhore, R., Tfayli, A., Manfaie, M., & Baillet-Guffroy, A. (2013). Vibra-
tional spectroscopy coupled to classical least square analysis, a new
approach for determination of skin moisturizing agents mechanisms.
Skin Research and Technology, 138(21), 1–11.
Weisshaar, E., & Pruritus im Alter. (2009). Ursachen und Therapiemöglich-
keiten. Ars Medici, 1, 10–14.
How to cite this article: Simon D, Nobbe S, Nägeli M, et al.
Short- and long-term effects of two emollients on itching and
skin restoration in xerotic eczema. Dermatologic Therapy.
2018;31:e12692. https://doi.org/10.1111/dth.12692
SIMON ET AL. 7 of 7
